Joseph S. Zakrzewski - 24 Mar 2022 Form 3 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Joseph Zakrzewski
Issuer symbol
ANTX
Transactions as of
24 Mar 2022
Net transactions value
$0
Form type
3
Filing time
24 Mar 2022, 21:26:44 UTC
Previous filing
01 Mar 2022
Next filing
31 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ANTX Common Stock 505,880 24 Mar 2022 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ANTX Stock Option (right to buy) 24 Mar 2022 Common Stock 99,999 $6.60 Direct F2
holding ANTX Series A Convertible Preferred Stock 24 Mar 2022 Common Stock 98,199 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held by Z3 Trust, for which the Reporting Person is a trustee.
F2 The shares subject to the option vest as follows: 1/36th of the shares vests monthly over three years from April 30, 2021, subject to the Reporting Person's continuous service as of such date.
F3 Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.

Remarks:

Exhibit 24 - Power of Attorney